In an FDA MedWatch update, the agency has issued an alert to HCPs, compounders, and patients about dosing errors that can occur as a result of patients measuring and self-administering incorrect doses of injectable semaglutide products. FDA has received reports of adverse events, including some that have required hospitalization.